Elanco Animal Health Incorporated $ELAN is Black Creek Investment Management Inc.’s Largest Position

Black Creek Investment Management Inc. reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,061,216 shares of the company’s stock after selling 1,421,245 shares during the quarter. Elanco Animal Health makes up approximately 12.4% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its largest position. Black Creek Investment Management Inc.’s holdings in Elanco Animal Health were worth $250,315,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Aigen Investment Management LP purchased a new stake in Elanco Animal Health in the 4th quarter valued at $681,000. Kestra Advisory Services LLC purchased a new stake in Elanco Animal Health in the 4th quarter valued at $168,000. CreativeOne Wealth LLC purchased a new stake in Elanco Animal Health in the 4th quarter valued at $1,260,000. Quartz Partners LLC grew its holdings in Elanco Animal Health by 5.7% in the 4th quarter. Quartz Partners LLC now owns 74,774 shares of the company’s stock valued at $1,692,000 after buying an additional 4,055 shares in the last quarter. Finally, Maverick Capital Ltd. grew its holdings in Elanco Animal Health by 240.4% in the 4th quarter. Maverick Capital Ltd. now owns 106,593 shares of the company’s stock valued at $2,412,000 after buying an additional 75,278 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ELAN. Citigroup upped their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Leerink Partners upped their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. KeyCorp upped their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $24.19 on Friday. The stock has a market cap of $12.08 billion, a PE ratio of -48.39, a P/E/G ratio of 1.58 and a beta of 1.69. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a twelve month low of $13.15 and a twelve month high of $27.72. The stock has a fifty day simple moving average of $22.90 and a 200-day simple moving average of $23.47.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.